Serial Troponin Trajectory Interpretation Tool

Clinical calculation support · Verify results before clinical use

Serial result review

Enter two high-sensitivity cardiac troponin results and the assay-specific 99th-percentile upper reference limit (URL). Use the same assay and units for both samples.

0 h + repeatTrajectory

Value at initial blood draw (0 h).

Record the actual sampling interval; validated pathways are time-dependent.

Use the correct laboratory limit for the assay and, where applicable, sex-specific reference limits.

Reset

Clinical interpretation

High-sensitivity cardiac troponin should be interpreted using a validated clinical decision pathway for the specific assay, sampling interval, and patient population. This page calculates the absolute and relative change and describes the relationship of both values to the entered URL; it is not a validated rule-in or rule-out algorithm.

Important principles

  • A cardiac troponin concentration above the assay-specific 99th-percentile URL indicates myocardial injury, not automatically myocardial infarction.
  • Acute myocardial injury is characterized by a rise and/or fall in cardiac troponin with at least one value above the 99th-percentile URL.
  • Myocardial infarction additionally requires clinical evidence of acute myocardial ischemia. Consider symptoms, ECG, imaging, and alternative causes of myocardial injury.
  • Use assay-specific absolute delta thresholds and exact sampling windows where a validated 0/1-hour or 0/2-hour pathway is implemented. Do not apply generic delta cutoffs across assays.
  • Ongoing or recurrent ischemic symptoms, ischemic ECG changes, hemodynamic instability, or a STEMI pattern require urgent clinical assessment; do not delay emergency care for this calculator.

Why fixed 5 ng/L and 20 ng/L cutoffs are not used here

The original file applied universal delta thresholds of 5 and 20 ng/L and linked the higher category to an early invasive strategy. These thresholds are not validated universally across hs-cTn assays or sampling intervals. The redesigned tool therefore avoids presenting those cutoffs as a diagnostic rule or using troponin change alone to recommend invasive management.

References

Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.

Recommends hs-cTn measurement as soon as possible and repeat sampling at 1–2 hours when the initial result is nondiagnostic; emphasizes assay-specific URL and diagnostic pathways.

JACC guideline (DOI: 10.1016/j.jacc.2024.11.009)
Byrne RA, et al. 2023 ESC Guidelines for the management of acute coronary syndromes.

Describes assay-specific ESC 0 h/1 h and 0 h/2 h pathways and the rule-out, observe, and rule-in categories.

European Heart Journal guideline (DOI: 10.1093/eurheartj/ehad191)
Thygesen K, et al. Fourth Universal Definition of Myocardial Infarction (2018).

Defines myocardial injury and myocardial infarction, including the need for evidence of ischemia to diagnose MI.

European Heart Journal (DOI: 10.1093/eurheartj/ehy462)
Clinical disclaimer: This tool is an aid for describing serial hs-cTn values, not a substitute for a validated assay-specific clinical decision pathway or clinician assessment. The entered URL must match the laboratory assay and relevant reference population. Results must be integrated with symptoms, ECG, timing of symptom onset, comorbidities, and the full clinical picture.